Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
The analyst also added that the rise of GLP-1s class drugs is not a major threat to insulin pump adoption.RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.
RBC資本市場對Tandem Diabetes Care, Inc.（納斯達克：TNDM）進行了研究覆蓋，該公司是一家全球胰島素傳遞和糖尿病技術公司，生產和銷售先進的自動胰島素傳遞系統。
The analyst highlights several key growth drivers for Tandem, positioning it for sustained growth over the coming years driven by expansion into the U.S. Type 1 market with a 40% pump penetration (Tandem has a one-third share), which is expected to rise to the mid-60s and Type 2 market with 6% penetration.
分析師指出Tandem的幾個關鍵增長驅動因素，使其定位於未來幾年的持續增長，擴張到美國的Type 1市場，泵式滲透率爲40%（Tandem佔三分之一市場份額），預計將升至中等60%的水平，以及Type 2市場，滲透率爲6%。
The company is also seeking deeper penetration within existing accounts through product innovations.
該公司還通過產品創新尋求加深在現有客戶帳戶內的滲透。
The analyst also added that the rise of GLP-1s class drugs is not a major threat to insulin pump adoption.
分析師還表示GLP-1類藥物的崛起不會對胰島素泵的採用構成重大威脅。
GLP-1 drugs such as Novo Nordisk A/S' (NYSE:NVO) semaglutide as Wegvoy and Ozempic and Eli Lilly And Co's (NYSE:LLY) tirzepatide as Zepbound and Mounjaro, have recently made waves.
諸如Novo Nordisk A/S的（紐交所：NVO）semaglutide（商業名稱Wegvoy和Ozempic）和Eli Lilly And Co的（紐交所：LLY）tirzepatide（商業名稱Zepbound和Mounjaro）等GLP-1類藥物最近引起轟動。
RBC analyst highlights that insulin is essential for insulin-dependent patients, as GLP-1 medications cannot regenerate beta cells or halt their deterioration. As a result, the need for insulin remains.
RBC分析師強調，對於依賴胰島素的患者，胰島素是必不可少的，因爲GLP-1藥物無法再生β細胞或阻止其退化。因此，對胰島素的需求仍然存在。
The Type 2 diabetes population, which suffers from irreversible beta cell loss, is underserved.
患有不可逆轉的β細胞流失的2型糖尿病人群得到了不足的服務。
The growing popularity of GLP-1 drugs may lead to earlier diagnoses of Type 2 diabetes and prompt insulin use, potentially expanding the market.
GLP-1藥物日益受歡迎可能會導致2型糖尿病的較早診斷並促使胰島素的使用，潛在地擴大市場。
RBC initiated Tandem with an Outperform, with a price target of $65, citing a significant upside potential driven by earning revisions and multiple expansions.
RBC對Tandem發起了強勁的買入評級，目標價爲65美元，原因是收益修訂和多次擴張推動着巨大的上行潛力。
RBC sees an opportunity for Tandem to achieve profitability over time and projects gross margins of 51% in 2024 or flat y/y to reflect the Mobi launch and investments in several ongoing R&D initiatives.
RBC認爲Tandem有機會隨着時間實現盈利，並預計2024年的毛利率爲51%，或年複合增長率持平，以反映Mobi的推出和對多項持續研發計劃的投資。
The analyst sees a clear path for the company to reach its goal of approximately 65% margins, with Mobi accounting for about half of that progress. Further gains are anticipated from planned initiatives.
分析師看到公司實現約65%利潤率的明確路徑，其中Mobi佔大約一半的進展。進一步的收益預計將來自計劃中的舉措。
RBC projects breakeven for 2024, with positive adjusted EBITDA margins expected in the second half of the year.
RBC預測2024年達到盈虧平衡，預計全年下半年將實現正調整EBITDA利潤率。
Price Action: TNDM stock is down 0.37% at $40.92 at the last check on Wednesday.
價格走勢：週三最後查詢時，TNDm股價下跌0.37%，報40.92美元。
- Toyota Doubles Down On Joby Aviation: $500M Investment Powers US Electric Air Taxi Certification, Production.
- 豐田加大對Joby Aviation的投資：5億美元的投資推動美國電動空中出租車認證和生產。
